Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05718921 · ClinicalTrials.gov registry record · Phase 1
A Safety, Tolerability and Pharmacokinetics Study of Topical Ointment YR001 in Adult Healthy Volunteers
A Phase 1 study of Atopic Dermatitis and Psoriasis, sponsored by Hangzhou Yirui Pharmaceutical Technology Co..
- Completed
- Registry status
- Phase 1
- Development phase
- 54
- Enrollment target
- 1
- Study location
NCT05718921: Completed Phase 1 study of Atopic Dermatitis and Psoriasis, sponsored by Hangzhou Yirui Pharmaceutical Technology Co..
NCT05718921 is a Phase 1 study of Atopic Dermatitis and Psoriasis that has completed, run by Hangzhou Yirui Pharmaceutical Technology Co.. The registered enrollment target is 54 participants, below the 609-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05718921, a Phase 1 study of Atopic Dermatitis and Psoriasis, has completed, sponsored by Hangzhou Yirui Pharmaceutical Technology Co..
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 54 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is to evaluate the safety, tolerability, and pharmacokinetics of YR001 topical ointment in healthy adult subjects.
Primary Outcome
Incidence of treatment related AEs (TRAEs) and local skin tolerance
Conditions Studied
Interventions
- DRUG YR001 Dose A on low body surface area
- DRUG YR001 Dose A on middle body surface area
- DRUG YR001 Dose A on high body surface area
- DRUG YR001 Dose B on low body surface area
- DRUG YR001 Dose B on middle body surface area
Study Locations (1)
California
- California Dermatology & Clinical Research Institute - Encinitas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 54 participants |
| Start Date | 2023-04-08 |
| Est. Completion | 2023-12-14 |
| Phase | Phase 1 |
What the finished NCT05718921 record still lists
NCT05718921 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 54 participants, a relatively small participant target, below the 609-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (91% lower).
The record links to 2 conditions, with Atopic Dermatitis appearing as the primary indexed condition, and to 5 interventions - of which YR001 Dose A on low body surface area is the first listed.
NCT05718921 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT05718921 about?
NCT05718921 is a clinical study titled "A Safety, Tolerability and Pharmacokinetics Study of Topical Ointment YR001 in Adult Healthy Volunteers". This study is to evaluate the safety, tolerability, and pharmacokinetics of YR001 topical ointment in healthy adult subjects.
What is the current status of trial NCT05718921?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 54 participants. The study started on 2023-04-08. Estimated completion is 2023-12-14.
What conditions does trial NCT05718921 study?
This clinical trial studies the following conditions: Atopic Dermatitis, Psoriasis.
What interventions are being tested in trial NCT05718921?
The interventions under investigation include: YR001 Dose A on low body surface area (DRUG), YR001 Dose A on middle body surface area (DRUG), YR001 Dose A on high body surface area (DRUG), YR001 Dose B on low body surface area (DRUG), YR001 Dose B on middle body surface area (DRUG).
Who is sponsoring clinical trial NCT05718921?
This trial is sponsored by Hangzhou Yirui Pharmaceutical Technology Co., which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05718921 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atopic Dermatitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05718921's enrollment target sits among peer trials
54 108th of 150 higher than 43 of 150 other Atopic Dermatitis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Atopic Dermatitis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Evaluating the Safety and Tolerability of Baricitinib in Patients With Job Syndrome With Lupus-Like Disease and/or Atopic Dermatitis
RECRUITING · Phase 1
-
Targeted Investigation of Microbiome 2 Treat Atopic Dermatitis (TIME-2)
RECRUITING · Phase 1
-
FIH Study to Evaluate the Tolerability of PF-07832837 in Healthy Adults and Patients
RECRUITING · Phase 1
-
A Study to Investigate the Safety, Tolerability, and Efficacy of BxC-I17e Single and Multiple Dose SC Injection in Patients With Moderate to Severe Atopic Dermatitis
RECRUITING · Phase 1
-
A Study of BBT001 in Healthy Volunteers (HVs) and in Adult Patients With Atopic Dermatitis (AD)
RECRUITING · Phase 1
-
A Study to Learn If the Study Medicine Called PF-08049820 Changes How the Body Processes the Other Study Medicines Called Oral Contraceptives, Midazolam, and Dabigatran in Healthy Adult Female Participants
ACTIVE NOT RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01269853 · 54 participants · Phase 1
Repeated Super-selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Relapsed GBM and AA
- NCT02390752 · 54 participants · Phase 1
Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor ...
- NCT02991248 · 54 participants · NA
Improve Dynamic Lateral Balance of Humans With SCI
- NCT02993900 · 54 participants · NA
Image-Guided Gynecologic Brachytherapy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI